JonesTrading has commenced coverage of Evaxion A/S (NASDAQ:EVAX), issuing a buy rating along with a price target of $10.00. This announcement was made in a research report published on Tuesday, March 5, 2024, as reported by Benzinga.
Several other analysts have also recently evaluated Evaxion’s stock. On the same day, Lake Street Capital reduced its price target from $11.00 to $9.00 while maintaining a buy rating. Additionally, the Maxim Group began coverage on February 19, 2024, also giving Evaxion a buy rating with a price objective of $10.00. HC Wainwright reaffirmed its buy rating with a target price of $16.00 on the same day.
In contrast, Weiss Ratings assigned a sell rating with a grade of “D-” on January 9, 2024. Overall, five analysts have issued buy ratings while one has labeled the stock as a sell. According to MarketBeat.com, Evaxion currently holds an average rating of “Moderate Buy” and an average price target of $11.00.
Recent Performance and Institutional Activity
Evaxion’s stock saw an increase of 8.0% following its quarterly earnings report on March 5, 2024. The company reported earnings per share (EPS) of $0.30 for the quarter. Analysts anticipate that Evaxion will post an EPS of -0.15 for the current year.
Institutional investors have been actively adjusting their positions in Evaxion. In the fourth quarter, Wesbanco Bank Inc. acquired a stake valued at $48,000, while Northwestern Mutual Wealth Management Co. invested $38,000. Additionally, SmartHarvest Portfolios LLC added a position worth $72,000. Currently, institutional investors hold 11.04% of Evaxion’s stock.
About Evaxion A/S
Based in Copenhagen, Denmark, with additional operations in the United States, Evaxion A/S is a clinical-stage biotechnology company. The firm specializes in the development of immunotherapies and vaccines, utilizing its proprietary AI-driven computational immunology platform. This advanced technology applies machine learning and deep learning algorithms to identify and optimize antigen targets for therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.
At the heart of Evaxion’s operations is its AI platform, which analyzes vast datasets encompassing genomic, proteomic, and immunological information to predict immune-stimulating epitopes. As the company continues to progress in its innovative approach, the market will be closely watching its developments.
For those interested in staying updated on Evaxion A/S, a daily summary of news and analyst ratings can be received through MarketBeat.com’s free newsletter.
